In patient samples with expression of both ROPN1B and NY-ESO-1, cells with exclusive ROPN1B positivity increased tumour cell coverage by 29.3% on average (range from 9.0% to 73.0%, Figure 3). This evidence concerns the gene ROPN1B and neoplasm.